One in Three Alzheimer, Dementia Cases Tied to Modifiable Risk Factors

WEDNESDAY, May 11, 2022 (HealthDay News) -- Midlife obesity, physical inactivity, and low education are the three most prominent modifiable risk factors associated with Alzheimer disease and related dementias (ADRDs), according to a study published online May 9 in JAMA Neurology.
Roch A. Nianogo, M.D., Ph.D., from University of California in Los Angeles, and colleagues estimated the proportion of ADRDs in the United States that are associated with modifiable risk factors and assessed differences by sex and race and ethnicity. Risk factor prevalence were estimated from the 2018 U.S. Behavioral Risk Factor Surveillance Survey (378,615 individuals), while relative risks for each risk factor were extracted from meta-analyses.
The researchers found that approximately one in three ADRD cases (36.9 percent) were associated with eight modifiable risk factors, the most prominent of which were midlife obesity (17.7 percent), physical inactivity (11.8 percent), and low educational attainment (11.7 percent). Men had higher combined population-attributable risks than women (35.9 versus 30.1 percent), with differences also seen by race and ethnicity (American Indian and Alaska Native individuals, 39 percent; Asian individuals, 16 percent; Black individuals, 40 percent; Hispanic individuals [any race], 34 percent; White individuals, 29 percent).
"Alzheimer risk reduction strategies may be more effective if they target higher-risk groups and consider current risk factor profiles," the authors write.
Abstract/Full Text (subscription or payment may be required)
Related Posts
Causal Link Identified Between Bipolar Disorder, IBD
FRIDAY, Oct. 21, 2022 (HealthDay News) -- Bipolar disorder (BD) is causally...
Escasea el Adderall, un medicamento para el TDAH
LUNES, 29 de agosto de 2022 (HealthDay News) -- La escasez de mano de obra en...
Blood Prick Test for Alzheimer’s Shows Promise
WEDNESDAY, July 19, 2023 (HealthDay News) -- A definitive diagnosis of...
Elon Musk’s Neuralink Says Brain-to-Computer Interface Has FDA Approval for Clinical Trial
FRIDAY, May 26, 2023 (HealthDay News) -- It may sound like the stuff of science...
